Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01762839 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Cardiac Safety of Oritavancin in Healthy Participants
A Phase 1 study, sponsored by Melinta Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 150
- Enrollment target
NCT01762839 is a Phase 1 study that has completed, run by Melinta Therapeutics. The registered enrollment target is 150 participants.
The verdict
NCT01762839, a Phase 1 study, has completed, sponsored by Melinta Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 150 participants
- Enrollment target
Study Summary
The purpose of the study was to generate cardiac safety data using a supratherapeutic oritavancin dose of 1600 milligrams (mg).
Interventions
- DRUG Placebo
- DRUG Moxifloxacin
- DRUG Single-Dose IV Oritavancin Diphosphate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2012-12-27 |
| Est. Completion | 2013-02-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01762839
The ClinicalTrials.gov registry entry for NCT01762839 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Melinta Therapeutics, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01762839 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01762839 about?
NCT01762839 is a clinical study titled "A Study to Assess the Cardiac Safety of Oritavancin in Healthy Participants". The purpose of the study was to generate cardiac safety data using a supratherapeutic oritavancin dose of 1600 milligrams (mg).
What is the current status of trial NCT01762839?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 150 participants. The study started on 2012-12-27. Estimated completion is 2013-02-11.
What interventions are being tested in trial NCT01762839?
The interventions under investigation include: Placebo (DRUG), Moxifloxacin (DRUG), Single-Dose IV Oritavancin Diphosphate (DRUG).
Who is sponsoring clinical trial NCT01762839?
This trial is sponsored by Melinta Therapeutics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.